Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Buse

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
The Journal of Experimental Medicine|August 1, 1985
Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN ratsJ B Buse, R Rifai-Haddad, S Lees, et al.
Diabetes|November 1, 1992
Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variationJ B Buse, K Yasuda, T P Lay, et al.
Diabetologia|April 25, 2012
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)S E Inzucchi, R M Bergenstal, J B Buse, et al.
Diabetes, Obesity & Metabolism|May 29, 2013
Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapyI B Hirsch, J B Buse, J Leahy, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observationsG H Daniels, L Hegedüs, S P Marso, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
The Journal of Experimental Medicine|August 1, 1985
Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN ratsJ B Buse, R Rifai-Haddad, S Lees, et al.
Diabetes|November 1, 1992
Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variationJ B Buse, K Yasuda, T P Lay, et al.
Diabetologia|April 25, 2012
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)S E Inzucchi, R M Bergenstal, J B Buse, et al.
Diabetes, Obesity & Metabolism|May 29, 2013
Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapyI B Hirsch, J B Buse, J Leahy, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observationsG H Daniels, L Hegedüs, S P Marso, et al.
Pageof 5